CA2610439A1 - Formes a dose unique de temozolomide - Google Patents

Formes a dose unique de temozolomide Download PDF

Info

Publication number
CA2610439A1
CA2610439A1 CA002610439A CA2610439A CA2610439A1 CA 2610439 A1 CA2610439 A1 CA 2610439A1 CA 002610439 A CA002610439 A CA 002610439A CA 2610439 A CA2610439 A CA 2610439A CA 2610439 A1 CA2610439 A1 CA 2610439A1
Authority
CA
Canada
Prior art keywords
days
patient
per day
day
day cycle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002610439A
Other languages
English (en)
Inventor
Jacqueline Rose Bersch
Mark Manzo
Sumant Ramachandra
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2610439A1 publication Critical patent/CA2610439A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4883—Capsule finishing, e.g. dyeing, aromatising, polishing

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La présente invention concerne des doses uniques de témozolomide. Ces doses uniques permettent d'alléger le schéma thérapeutique et d'augmenter l'adhésion du patient. L'invention concerne également des procédés destinés au traitement de troubles évolutifs chez un patient, consistant à utiliser ces doses uniques. L'invention concerne également des trousses comprenant ces doses uniques.
CA002610439A 2006-06-26 2007-06-25 Formes a dose unique de temozolomide Abandoned CA2610439A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81662306P 2006-06-26 2006-06-26
US60/816,623 2006-06-26
PCT/US2007/014761 WO2008002544A2 (fr) 2006-06-26 2007-06-25 Doses uniques de témozolomide

Publications (1)

Publication Number Publication Date
CA2610439A1 true CA2610439A1 (fr) 2007-12-26

Family

ID=38704663

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002610439A Abandoned CA2610439A1 (fr) 2006-06-26 2007-06-25 Formes a dose unique de temozolomide

Country Status (13)

Country Link
EP (1) EP1901740A2 (fr)
JP (1) JP2008534692A (fr)
KR (2) KR20100055543A (fr)
CN (1) CN101309686A (fr)
AR (1) AR061618A1 (fr)
AU (1) AU2007221979A1 (fr)
BR (1) BRPI0702847A (fr)
CA (1) CA2610439A1 (fr)
CL (1) CL2007001864A1 (fr)
NO (1) NO20074913L (fr)
TW (1) TWI326598B (fr)
WO (1) WO2008002544A2 (fr)
ZA (1) ZA200708280B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102526038B (zh) * 2011-01-12 2013-09-11 北京人福军威医药技术开发有限公司 替莫唑胺的脑靶向药物组合物及其应用
US10744171B2 (en) * 2016-03-21 2020-08-18 Duke University Sequential anti-cancer treatment
US11147810B2 (en) 2017-03-13 2021-10-19 Ftf Pharma Private Limited Pharmaceutical composition of oral suspension of anti-neoplastic alkylating agents

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2251987T3 (es) * 1999-03-30 2006-05-16 Schering Corporation Tratamiento mejorado del cancer con temozolomida.
US20060100188A1 (en) * 2004-11-09 2006-05-11 Chen Zong Treatment methods

Also Published As

Publication number Publication date
WO2008002544A2 (fr) 2008-01-03
WO2008002544A3 (fr) 2008-02-07
KR20080015777A (ko) 2008-02-20
JP2008534692A (ja) 2008-08-28
AR061618A1 (es) 2008-09-10
BRPI0702847A (pt) 2008-04-01
CN101309686A (zh) 2008-11-19
ZA200708280B (en) 2009-03-25
EP1901740A2 (fr) 2008-03-26
AU2007221979A9 (en) 2008-01-10
KR20100055543A (ko) 2010-05-26
AU2007221979A1 (en) 2008-01-10
NO20074913L (no) 2009-03-26
TWI326598B (en) 2010-07-01
TW200808803A (en) 2008-02-16
CL2007001864A1 (es) 2008-02-08

Similar Documents

Publication Publication Date Title
AU2005304672B2 (en) Improved dosing regimen of temozolomide for treating cancer based on the patient's MGMT level
US20100210700A1 (en) Methods of treatment using intravenous formulations comprising temozolomide
US20080090242A1 (en) Panel of biomarkers for prediction of fti efficacy
US20080319039A1 (en) Unit dosage forms of temozolomide
CA2610439A1 (fr) Formes a dose unique de temozolomide
Alméciga-Díaz et al. Virtual screening of potential inhibitors for SARS-CoV-2 main protease
US20100240723A1 (en) Methods of treating cell proliferative disorders using a compressed temozolomide dosing schedule
Yu et al. BRCA1 overexpression sensitizes cancer cells to lovastatin via regulation of cyclin D1-CDK4-p21WAF1/CIP1 pathway: analyses using a breast cancer cell line and tumoral xenograft model
MX2007012093A (en) Unit dosage forms of temozolomide
US7045523B2 (en) Combination comprising N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and telomerase inhibitor
Yung Future directions for temozolomide therapy
US20220356525A1 (en) Methods of determining whether patients suffering from acute myeloid leukemia will achieve a response to an myc-targeting therapy
KR20240026704A (ko) Ginsenoside Rk1을 포함하는 전립선암 예방 또는 치료용 약학적 조성물
EP3923987A1 (fr) Utilisation d'inhibiteurs de l'usp7 pour le traitement de la leucémie aiguë myéloïde (lam)
Srivastava et al. CANCER CHEMOTHERAPYSONAL SRIVASTAVA, SAKSHI MISHRA, JAYANT DEWANGAN, AMAN DIVAKAR, PRABHASH KUMAR PANDEY, ANDSRIKANTA KUMAR RATH

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20140625